A Mild, Efficient Approach for the Synthesis of 1,5-Disubstituted Hydantoins
ture was stirred overnight (unless otherwise noted). When needed
Acknowledgments
(see Tables 1 and 2), aqueous 2 NaOH (10% in volume) was
added, and the mixture was stirred for 15 min. Aqueous 1 HCl
was added until acidic pH, and the resulting mixture was extracted
with DCM. The combined organic layer was dried with anhydrous
Na2SO4, filtered and concentrated under vacuum. The crude was
purified by flash chromatography.
Politecnico di Milano (Progetto Giovani Ricercatori 2007–2008) is
gratefully acknowledged for economic support.
[1] J. C. Thenmozhiyal, P. T. H. Wong, W. K. Chui, J. Med. Chem.
2004, 47, 1527–1535.
Diethyl 2-(1-tert-Butyl-3-cyclohexyl-2,5-dioxoimidazolidin-4-yl)ma-
lonate (3b): Rf = 0.53 (hexane/AcOEt, 80:20). 1H NMR (400 MHz,
CDCl3): δ = 4.27 (d, J = 4.2 Hz, 1 H), 4.14 (m, 4 H), 3.86 (d, J =
4.2 Hz, 1 H), 3.56 (m, 1 H), 1.63 (m, 6 H), 1.51 (s, 9 H), 1.21 (t, J
= 7.3 Hz, 3 H), 1.19 (t, J = 7.8 Hz, 3 H), 1.16 (m, 2 H) ppm. 13C
NMR (125.7 MHz, CDCl3): δ = 171.3, 168.9, 157.3, 62.2, 61.7,
56.6, 53.5, 53.2, 31.3, 30.2, 28.5, 25.9, 25.2, 14.1, 14.0 ppm. MS
(ESI): m/z (%) = 397.1 (22) [M+ + H], 419.1 (100) [M+ + Na], 435.1
(14) [M+ + K].
[2] a) C. W. Bazil, T. A. Pedley, Annu. Rev. Med. 1998, 49, 135–
162; b) M. S. Luer, Neurol. Res. 1998, 20, 178–182.
[3] a) M. Matsukura, Y. Daiku, K. Ueda, S. Tanaka, T. Igarashi,
N. Minami, Chem. Pharm. Bull. 1992, 40, 1823–1827; b) J.
Knabe, J. Baldauf, A. Ahlhelm, Pharmazie 1997, 52, 912–919.
[4] L. Somsák, L. Kovács, M. Tóth, E. Ösz, L. Szilágyi, Z. Györ-
gydeák, Z. Dinya, T. Docsa, B. Tóth, P. Gergely, J. Med. Chem.
2001, 44, 2843–2848.
[5] a) G. P. Moloney, A. D. Robertson, G. R. Martin, S. MacLen-
nan, N. Mathews, S. Dosworth, P. Y. Sang, C. Knight, R. Glen,
J. Med. Chem. 1997, 40, 2347–2362; b) G. P. Moloney, G. R.
Martin, N. Mathews, A. Milne, H. Hobbs, S. Dosworth, P. Y.
Sang, C. Knight, M. Williams, M. Maxwell, R. Glen, J. Med.
Chem. 1999, 42, 2504–2526.
[6] M. Jansen, H. Potschka, C. Brandt, W. Löscher, G. Dannhardt,
J. Med. Chem. 2003, 46, 64–73.
[7] K. Last-Barney, W. Davidson, M. Cardozo, L. L. Frye, C. A.
Grygon, J. L. Hopkins, D. D. Jeanfavre, S. Pav, C. Qian, J. M.
Stevenson, L. Tong, R. Zindell, T. A. Kelly, J. Am. Chem. Soc.
2001, 123, 5643–5650.
[8] J. C. Sutherland, G. P. Hess, Nat. Prod. Rep. 2000, 17, 621–631.
[9] a) C. Syldatk, R. Müller, M. Siemann, K. Krohn, F. Wagner,
Biocatalytic Production of Amino Acids and Derivatives, Hanser,
München, 1992, p. 75; b) K. Drauz, H. Waldmann, Enzyme
Catalysis in Organic Synthesis, VCH, Weinheim, 1995, p. 409.
[10] C. A. López, G. G. Trigo, Adv. Heterocycl. Chem. 1985, 38,
177–228.
[11] a) S. W. Kim, S. Y. Ahn, J. S. Koh, J. H. Lee, S. Ro, H. Y. Cho,
Tetrahedron Lett. 1997, 38, 4603–4606; b) J. Matthews, R. A.
Rivero, J. Org. Chem. 1997, 62, 6090–6092; c) M. M. Sim, A.
Ganesan, J. Org. Chem. 1997, 62, 3230–3235.
Diethyl
2-(3-Butyl-2,5-dioxo-1-tritylimidazolidin-4-yl)malonate
(3aa): Rf = 0.39 (hexane/AcOEt, 80:20). 1H NMR (400 MHz,
CDCl3): δ = 7.42 (m, 6 H), 7.16–7.14 (m, 9 H), 4.24 (d, J = 2.6 Hz,
1 H), 4.19–4.12 (m, 4 H), 4.00 (d, J = 2.6 Hz, 1 H), 3.52 (m, 1 H),
2.94 (m, 1 H), 1.36 (m, 2 H), 1.22 (t, J = 7.0 Hz, 3 H), 1.17 (t, J =
7.0 Hz, 3 H), 0.98 (m, 2 H) ppm. 13C NMR (62.9 MHz, CDCl3): δ
= 170.3, 166.9, 165.6, 156.2, 142.4, 128.6, 127.3, 126.5, 74.0, 62.3,
62.1, 57.3, 52.8, 41.5, 29.0, 19.4, 13.95, 13.96, 13.5 ppm. MS (ESI):
m/z (%) = 579.2 (100) [M+ + Na], 557.1 (8) [M+ + H].
General Procedure for N-tert-Butyl Deprotection: A stirred solution
of hydantoin 3 (1 equiv.) and CH3SO3H (10% in volume) in DCM
(0.5 solution) was heated at 60 °C in a sealed tube for 3 h. The
solution was cooled to room temperature, diluted with aqueous
5% NaHCO3 until basic and extracted with DCM. The combined
organic layer was dried with anhydrous Na2SO4, filtered and con-
centrated under vacuum. When necessary, the crude was purified
by flash chromatography.
Diethyl 2-(2,5-Dioxo-3-phenylimidazolidin-4-yl)malonate (11a): Rf =
0.34 (hexane/AcOEt, 60:40). 1H NMR (400 MHz, CDCl3): δ = 8.64
(br. s, 1 H), 7.34–7.28 (m, 5 H), 5.16 (d, J = 4.2 Hz, 1 H), 4.28 (q,
J = 7.0 Hz, 2 H), 4.11 (m, 2 H), 3.92 (d, J = 4.2 Hz, 1 H), 1.30 (t,
J = 7.0 Hz, 3 H), 1.18 (t, J = 7.0 Hz, 3 H) ppm. 13C NMR
(100.6 MHz, CDCl3): δ = 169.9, 165.5, 165.4, 154.4, 134.4, 129.5,
126.9, 123.8, 62.6, 62.1, 60.3, 50.9, 13.9, 13.8 ppm. MS (ESI): m/z
(%) = 335.0 (6) [M+ + H], 357.0 (100) [M+ + Na].
[12] A. Boeijen, J. A. W. Kruijtzer, R. M. Liskamp, Bioorg. Med.
Chem. Lett. 1998, 8, 2375–2380.
[13] a) B. A. Dressman, L. A. Spangle, S. W. Kaldor, Tetrahedron
Lett. 1996, 37, 937–940; b) K. H. Park, M. J. Kurth, Tetrahe-
dron Lett. 2000, 41, 7409–7413; c) M. Lamothe, M. Lannuzel,
M. Perez, J. Comb. Chem. 2002, 4, 73–78; d) A. Nefzi, M. Giul-
ianotti, L. Troung, S. Rattan, J. M. Ostresh, R. A. Houghten,
J. Comb. Chem. 2002, 4, 175–178; e) J. Vázquez, M. Royo, F.
Albericio, Lett. Org. Chem. 2004, 1, 224–226; f) C. Hulme, L.
Ma, J. J. Romano, G. Morton, S. Y. Tang, M. P. Cherrier, S.
Choi, J. Salvino, R. Labaudiniere, Tetrahedron Lett. 2000, 41,
General Procedure for N-Trityl Deprotection: A solution of hydan-
toin 3 (1 equiv.), Et3SiH (4 equiv.) and TFA (10% in volume) in
DCM (0.5 solution) was stirred at room temperature until all the
starting material was consumed (TLC monitoring). The solution
was diluted with aqueous 5% NaHCO3 until basic and extracted
with DCM. The combined organic layer was dried with anhydrous
Na2SO4, filtered and concentrated under vacuum, and the crude
was purified by flash chromatography.
1889–1893; g) M. Meusel, A. Ambrozak, T. K. Hecker, M.
˙
Gütschow, J. Org. Chem. 2003, 68, 4684–4692; h) M. Beller, M.
Eckert, W. A. Moradi, H. Neumann, Angew. Chem. Int. Ed.
1999, 38, 1454–1456; i) B. Zhao, H. Du, Y. Shi, J. Am. Chem.
Soc. 2008, 130, 7220–7221.
[14] a) A. Volonterio, M. Zanda, Tetrahedron Lett. 2003, 44, 8549–
8551; b) A. Volonterio, C. Ramirez de Arellano, M. Zanda, J.
Org. Chem. 2005, 70, 2161–2170; c) F. Olimpieri, A. Volonterio,
M. Zanda, Synlett 2008, 3016–3020.
Ethyl 2-(3-Benzyl-2,5-dioxoimidazolidin-4-yl)acetate (11e): Rf
=
[15] O. O. Orazzi, R. A. Corral, Experientia 1965, 21, 508.
[16] a) J. A. Monn, M. J. Valli, S. M. Massey, R. A. Wright, C. R.
Salhoff, B. G. Johnson, T. Howe, C. A. Alt, G. A. Rhodes,
R. L. Robey, K. R. Griffey, J. P. Tizzano, M. J. Kallman, D. R.
Helton, D. D. Schoepp, J. Med. Chem. 1997, 40, 528; b) J. A.
Monn, M. J. Valli, S. M. Massey, M. M. Hansen, T. J. Kress,
J. P. Wepsic, A. R. Harkness, J. L. Grutsch, R. A. Wright, B. G.
Johnson, S. Andis, L. A. Kingston, R. Tomlinson, R. Lewis,
K. R. Griffey, J. P. Tizzano, D. D. Schoepp, J. Med. Chem.
1999, 42, 1027; c) F. Tellier, F. Acher, I. Brabet, J. P. Pin, R.
Azerad, Bioorg. Med. Chem. 1998, 6, 195.
0.24 (hexane/AcOEt, 50:50). 1H NMR (400 MHz, CDCl3): δ = 8.54
(br. s, 1 H), 7.33 (m, 5 H), 4.77 (d, J = 15.6 Hz, 1 H),4.30 (d, J =
15.6 Hz, 1 H),4.14 (t, J = 4.8 Hz, 1 H), 4.08 (m, 2 H), 2.78 (d, J =
4.8 Hz, 2 H), 1.19 (t, J = 7.6 Hz, 3 H) ppm. 13C NMR (125.7 MHz,
CDCl3): δ = 172.4, 168.9, 135.8, 129.0, 128.2, 128.1, 61.4, 57.3,
45.1, 34.1, 14.0 ppm. MS (ESI): m/z (%) = 277.2 [M++H, (100)].
Supporting Information (see footnote on the first page of this arti-
cle): The spectroscopic data for all the remaining compounds and
the copies of the 1H and 13C NMR spectra for all new compounds.
Eur. J. Org. Chem. 2009, 6179–6188
© 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
www.eurjoc.org
6187